
|Articles|September 15, 2002
Macugen research: Enrollment ends early in trials for wet AMD drug
New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
UPDATE: STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
Research supports that iron dysregulation may drive AMD
3
Advancements in femtosecond laser technology benefit surgeons and patients
4
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide
5

















































.png)


